Prostate News
Latest Health News and Medical News posted throughout the day, every day.
Updated: 28 weeks 2 days ago
Fighting Prostate Cancer With Speed And Accuracy: RapidArc(R) Radiotherapy Available At The Delaware Valley Urology Cancer Treatment Center
Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five...
Categories: Men's Health News
Affiliate Partnership Between EAU And Europa Uomo
The European Association of Urology (EAU) and Europa Uomo, the European advocacy movement for the fight against prostate cancer, have entered into an affiliated partnership as part of their long-term commitment to increase and improve patient awareness in Europe with regards to urological diseases...
Categories: Men's Health News
The Role Of Biopsy Core Number In Selecting Prostate Cancer Patients For Active Surveillance
UroToday.com - Active surveillance (AS) entails a strategy by which selected men are managed expectantly with the intention of applying potentially curative treatment in case of signs of progression. While AS strategy has changed the treatment and management of low-risk prostate cancers, it must also evolve as a diagnostic tool...
Categories: Men's Health News
Biopsy Schemes With The Fewest Cores For Detecting 95% Of The Prostate Cancers Detected By A 24-Core Biopsy
UroToday.com - Transrectal ultrasound with prostate biopsy (TRUS/Bx) remains the method for detection of prostate cancer (CaP) in men with an elevated PSA or abnormal digital rectal examination. It is clear that the methodology of sampling will influence the detection rate of CaP. In the online edition of European Urology, Dr...
Categories: Men's Health News
Freedom From A Detectable Ultrasensitive Prostate-Specific Antigen At Two Years After Radical Prostatectomy Predicts A Favorable Clinical Outcome
UroToday.com - In the online edition of Urology, Dr. Steven Chang and associates from the SEARCH database report that time to first detectable ultrasensitive PSA (uPSA) identifies men with low-risk recurrence prostate cancer (CaP). PSA doubling time (PSADT) 0...
Categories: Men's Health News
Natural History Of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From The SEARCH Database
UroToday.com - A prostate specific antigen (PSA) level that does not nadir after radical prostatectomy (RP) suggests residual benign or malignant local disease, or metastatic disease that occurred prior to surgery. In the November 2009 online edition of the Journal of Urology, Dr...
Categories: Men's Health News
Prospective Study Of Determinants And Outcomes Of Deferred Treatment Or Watchful Waiting Among Men With Prostate Cancer In A Nationwide Cohort
UroToday.com - In the online edition of the Journal of Clinical Oncology, Dr. William Shappley and associates reported on a prospective cohort of men with prostate cancer (CaP) who were followed with active surveillance with deferred treatment (DT) intervention. The participants were from the Health Professionals Follow-up Study (HPFS)...
Categories: Men's Health News
Can Residents Perform Transrectal Ultrasound-Guided Prostate Biopsy With Patient Comfort Comparable To Biopsy Performed By Attending Staff Urologists?
UroToday.com - Urology residents are involved with performing transrectal-ultrasound (TRUS) guided prostate biopsies during their training. Satisfactory accomplishment of this skill is a competency necessary for urologic practice...
Categories: Men's Health News
XMRV Is Present In Malignant Prostatic Epithelium And Is Associated With Prostate Cancer, Especially High-Grade Tumors
UroToday.com - In the September 22, 2009 issue of the Proceedings of the National Academy of Sciences, Dr. Robert Schlaberg and colleagues verify that the DNA and protein from the xenotropic murine leukemia virus-related virus (XMRV) exists in prostate cancer (CaP) tissue...
Categories: Men's Health News
Prostate Cancer Diagnosis And Treatment After The Introduction Of Prostate-Specific Antigen Screening: 1986-2005
UroToday.com - Screening and early detection should identify cancers that will become clinically relevant. In this case, the number of individuals diagnosed with cancer would be unaffected by screening. However, early detection can be associated increases in incidence, raising the question of over-diagnosis. Cancers that are found by over-diagnosis never progress to cause symptoms or death...
Categories: Men's Health News
Ipsen's Decapeptyl(R) 6-Month Formulation Receives Marketing Authorization For The Treatment Of Locally Advanced Or Metastatic Prostate Cancer
Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate1 22...
Categories: Men's Health News
Comparative Effectiveness Of Minimally Invasive Vs Open Radical Prostatectomy
UroToday.com - Minimally invasive radical prostatectomy (MIRP) for prostate cancer (CaP) is the most common treatment modality for localized CaP in the United States. The popularity in part is due to marketing and patient driven desire for the procedure. This encompasses both pure laparoscopic radical prostatectomy and robotic-assisted radical prostatectomy...
Categories: Men's Health News
ProUroCare Medical Announces Filing Of 510(k) For Prostate Imaging System
ProUroCare Medical Inc. (OTCBB: PUMD) (OTCBB: PUMDU) (OTCBB: PUMDW), a provider of proprietary medical imaging products, announced that a 510(k) application for U.S. market clearance of a prostate mechanical imaging system has been filed with the Food & Drug Administration (FDA)...
Categories: Men's Health News
Dendreon Receives FDA Acknowledgement Of Complete Response
Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA...
Categories: Men's Health News
Multidisciplinary Meeting On Urological Cancers
Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level...
Categories: Men's Health News
Tulane Cancer Center To Begin Novel Clinical Trial For Late-Stage Prostate Cancer Drug
International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide...
Categories: Men's Health News
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets Conference
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC)...
Categories: Men's Health News
Anxiety And Distress During Active Surveillance For Early Prostate Cancer
UroToday.com - The present study found that the majority of men with early prostate cancer (PC) included in a protocol-based program for active surveillance (AS) show favorable anxiety and distress scores when compared to reference values and to groups of patients with PC who underwent other treatments...
Categories: Men's Health News
Percentage Of Positive Biopsy Cores At The Onset Of Hormone Therapy For Prostate Cancer: Prognostic Significance
UroToday.com - Accurate prediction of outcome after hormonal treatment for localized prostate cancer is important for patient counselling, follow-up, treatment planning and research protocol design. Few prognostic tools incorporating pre-therapeutic parameters are available to increase disease relapse predictions and survival...
Categories: Men's Health News
Degarelix: A New Approach For The Treatment Of Prostate Cancer
UroToday.com - Gonadotrophin-releasing hormone (GnRH) agonists are currently the 'standard of care' for androgen deprivation therapy (ADT) in prostate cancer. Improvements in ADT would have a great value for many patients...
Categories: Men's Health News
